Kamini Raghuram | Drug Safety and Risk Management | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Kamini Raghuram | Drug Safety and Risk Management | Best Researcher Award

Staff Neonatologist and Developmental Pediatrician at University of Toronto | Canada

Dr. Kamini Raghuram is a clinician-scientist specializing in developmental and behavioral pediatrics, neonatal-perinatal medicine, and clinical epidemiology. With a strong foundation in pediatrics, she has combined clinical expertise with cutting-edge research to advance outcomes in high-risk and preterm infants. Her work bridges clinical practice, epidemiology, and innovative technological tools such as automated video-based analysis for motor impairment. Dr. Raghuram has been a principal and co-investigator on numerous funded projects and has published extensively in leading pediatric and neonatal journals. She is widely recognized for her dedication to improving long-term neurodevelopmental outcomes in vulnerable infant populations.

Publication Profile 

Orcid

Education 

Dr. Kamini Raghuram completed her Doctor of Medicine (MD) at the University of Toronto, followed by FRCPC training in General Pediatrics, Neonatal and Perinatal Medicine, and Developmental and Behavioral Pediatrics at the same institution. She earned a Master of Science in Clinical Epidemiology and Health Care Research from the Institute of Health Policy, Management, and Evaluation, University of Toronto, where her thesis focused on video-based motor impairment analysis in preterm infants. Earlier, she obtained a Bachelor of Applied Science in Chemical and Biological Engineering from the University of British Columbia, graduating as class valedictorian and recognized for outstanding research proficiency.

Experience 

Dr. Kamini Raghuram has held extensive clinical and academic positions across pediatrics, neonatology, and developmental medicine. She has served as a clinician-investigator, integrating patient care with translational research to develop evidence-based approaches for preterm infants. Her work includes leading clinical trials, advancing quality improvement initiatives, and applying machine learning and automated video analysis for early detection of motor and neurodevelopmental impairments. With expertise spanning neonatal intensive care, developmental follow-up, and health outcomes research, she has collaborated nationally and internationally to improve clinical pathways for high-risk infants. Her experience reflects a unique combination of bedside practice and pioneering research in pediatrics.

Awards and Honors 

Dr. Kamini Raghuram has received numerous awards and funding recognitions for her research and clinical excellence. These include CIHR grants exceeding $2 million, innovation fund competitions, and recognition for her work on neonatal outcomes. She has won presentation and research awards at the University of Toronto, The Hospital for Sick Children, and international conferences. Honors such as the Excellence in Academic Coaching Award, Quality Improvement Award, Canada Graduate Scholarship, and early-career fellowships highlight her leadership and academic impact. Earlier, as an engineering student, she received the Lefevre Gold Medal and delivered the valedictorian address at the University of British Columbia.

Research Focus 

Dr. Kamini Raghuram research focuses on improving neurodevelopmental and health outcomes in preterm and high-risk infants through early detection, intervention, and long-term follow-up strategies. She applies advanced tools, including automated video analysis, MRI biomarkers, and large-scale database studies, to identify predictors of motor and cognitive impairment. Her work integrates clinical epidemiology with neonatal and developmental pediatrics, emphasizing translational approaches from bench to bedside. She is also involved in clinical trials addressing interventions such as coadministration therapies and surgical decision-making in fetal medicine. Her ultimate goal is to enhance early diagnosis, optimize interventions, and improve quality of life for vulnerable children.

Publication Top Notes

Caregiver Experiences, Healthcare Provider Perspectives and Child Outcomes with Virtual Care in a Neonatal Neurodevelopmental Follow-Up Clinic: A Mixed-Methods Study

Automated Movement Analysis to Predict Cerebral Palsy in Very Preterm Infants: An Ambispective Cohort Study

Conclusion

Dr. Kamini Raghuram is a highly deserving candidate for the Best Researcher Award. Her career reflects a rare combination of clinical excellence, research innovation, and dedication to improving outcomes for preterm infants. With substantial grant funding, groundbreaking studies in automated movement analysis, and leadership in advancing neonatal care, she exemplifies the qualities of a leading researcher. While opportunities exist to expand her global influence and further scale her innovations, her proven track record of impactful, patient-centered research makes her an outstanding nominee for this prestigious recognition.

Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Associate Researcher at Hainan Institute of Zhejiang University | China

Dr. Muhammad Musa Khan is a Pakistani entomologist and research scientist with an extensive background in agricultural entomology, insect toxicology, and pest management. Currently serving as an Associate Researcher at the Hainan Institute of Zhejiang University, China, he focuses on pesticide toxicity, ecological risk assessment, and resistance management in agroecosystems. His research spans ecological, molecular, and toxicological approaches to pest control. Dr. Khan has published prolifically in high-impact journals and is recognized for advancing sustainable pest management strategies. His collaborative, multidisciplinary work integrates field ecology with molecular diagnostics, benefiting both science and agriculture on a global scale.

Publication Profile 

Google Scholar

Education 

Dr. Khan earned his Ph.D. in Agricultural Entomology and Pest Control from Huazhong Agricultural University, China, where he worked on predator safety in rice ecosystems. He completed his M.Sc. (Hons) in Entomology from the University of Agriculture Faisalabad, Pakistan, researching resistance mechanisms in cotton against sap-sucking pests. His undergraduate degree (B.Sc. Hons) in Agriculture with a specialization in Entomology was obtained from PMAS Arid Agriculture University, Rawalpindi. Additionally, he interned at the Nuclear Institute for Agriculture and Biology, gaining hands-on expertise in biological control agent rearing and field application methods.

Experience 

Dr. Khan currently serves as Associate Researcher at the Hainan Institute of Zhejiang University, China, investigating pesticide toxicity and resistance in brown planthopper and rice ecosystems. His previous role as a Postdoctoral Researcher at South China Agricultural University involved studying the effects of UV light on whiteflies and moths. During his Ph.D., he explored ecotoxicological risks of insecticides on beneficial insects and tested essential oil-based pest repellent strategies. His scientific skillset encompasses molecular biology techniques, gene expression analysis, bioinformatics, and biostatistics. His interdisciplinary approach allows integration of molecular diagnostics with field-level pest management.

Awards and Honors 

Dr. Khan has received significant recognition for his impactful research, including editorial contributions to international journals such as Frontiers in Plant Science. His publications have consistently appeared in top-tier Q1 journals like Journal of Hazardous Materials and Chemosphere. As a corresponding author and equal first author, his contributions are well-acknowledged in international collaborations. His work has received citations and global visibility for its originality in ecological toxicology and entomological innovation. Moreover, his involvement in multiple Chinese institutions and his role in international research networks reflect his growing influence and leadership in the agricultural research community.

Research Focus 

Dr. Khan’s research bridges entomology, toxicology, and molecular biology with a primary focus on insecticide resistance, non-target toxicity, and ecological safety in agroecosystems. He specializes in assessing chemical and environmental stressors on pests and their natural enemies, especially in rice and vegetable production systems. His studies utilize DNA/RNA techniques, gene expression profiling, and biochemical assays to decipher the molecular impact of pesticides and ultraviolet exposure on pest physiology and behavior. He is particularly interested in predator-prey dynamics, pollinator safety, integrated pest management, and sustainable solutions to enhance agricultural productivity while minimizing ecological harm.

Publication Top Notes

Role of insect gut microbiota in pesticide degradation: a review

Metabolic-based insecticide resistance mechanism and ecofriendly approaches for controlling of beet armyworm Spodoptera exigua: a review

Impact of invasive ant species on native fauna across similar habitats under global environmental changes

Lethal and sublethal effects of emamectin benzoate on the rove beetle, Paederus fuscipes, a non-target predator of rice brown planthopper, Nilaparvata lugens

Identification of attractants from plant essential oils for Cyrtorhinus lividipennis, an important predator of rice planthoppers

Role of digestive protease enzymes and related genes in host plant adaptation of a polyphagous pest, Spodoptera frugiperda

Temperature-Dependent Functional Response of Harmonia axyridis (Coleoptera: Coccinellidae) on the Eggs of Spodoptera litura (Lepidoptera: Noctuidae) in …

Lethal and Sublethal Effects of Chlorpyrifos on Biological Traits and Feeding of the Aphidophagous Predator Harmonia axyridis

Sublethal effects of chlorantraniliprole on Paederus fuscipes (Staphylinidae: Coleoptera), a general predator in paddle field

Using a Two-Sex Life Table Tool to Calculate the Fitness of Orius strigicollis as a Predator of Pectinophora gossypiella

Insecticide resistance and detoxification enzymes activity in Nilaparvata lugens Stål against neonicotinoids

Emamectin benzoate induced enzymatic and transcriptional alternation in detoxification mechanism of predatory beetle Paederus fuscipes (Coleoptera: Staphylinidae) at the …

Taro Shibuki | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. 🎓 He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. 🏥 His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. 🔍✨

Publication Profile

orcid

Education

Dr. Taro Shibuki 🎓 is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies 📖, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards 🏆 for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. 🚀

Research and Innovations

Dr. Taro Shibuki 🔬 is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) 📑, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach 🚀, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. 🏥

Scientific Contributions

Dr. Taro Shibuki 📚 is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics 🔍, and metabolomics 🧪 to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) 🏥 assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. 🚀

Editorial Roles

Dr. Taro Shibuki ⚕️ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) 🏥 plays a crucial role in clinical innovation. His research in drug development 💊 and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress 🔬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. 🚀

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies 🏥. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors 🏆 for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases 🔬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. 🚀

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology 🔬, with a particular focus on precision medicine 🧬, pancreatic cancer 🏥, and biliary tract cancer 🧑‍⚕️. His work involves optimizing chemotherapy 💊 and developing advanced stent deployment techniques 🏗️ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects 🧑‍🔬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics 🏥 and therapeutic strategies 💡, striving for a quantum leap in oncology 🚀 by integrating molecular profiling 🧬 and cutting-edge clinical approaches 🏥.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Ms. Tahere Abdollahi |Drug Safety and Risk Management |Women Researcher Award

Published on by Top Pharmaceutical

Ms. Tahere Abdollahi|Drug Safety and Risk Management |Women Researcher Award

Ms. Tahere Abdollahi at Hamadan University of Medical Sciences,Iran

PROFILE  

Orcid

Early Academic Pursuits 🎓

Tahere Abdollahi embarked on her academic journey with a strong foundation in Occupational Health Engineering. She pursued a Master’s degree in this field at Hamadan University of Medical Sciences, which is renowned for producing professionals with expertise in healthcare and occupational safety. Her academic focus on occupational health was driven by a passion for improving workplace environments, particularly in industries dealing with hazardous substances. During her early years as a student, Tahere developed a keen interest in the impact of industrial chemicals and drugs on human health, a theme that would shape her future research.

Her commitment to academic excellence allowed her to gain a comprehensive understanding of the science of occupational health. She was actively involved in laboratory work, field studies, and academic discussions, all of which solidified her knowledge base in the subject. These early academic experiences laid the groundwork for her future endeavors as an occupational health consultant and researcher.

Professional Endeavors 👩‍⚕️

Currently, Tahere Abdollahi holds a significant role as an Occupational Health Consultant in the medical equipment industry. Her expertise allows her to offer critical insights into the health risks associated with medical environments and equipment, ensuring that workers in this sector remain protected from occupational hazards. Her consulting work extends to evaluating the safety of equipment used in healthcare settings, as well as suggesting improvements to reduce potential risks.

In addition to her consulting role, Tahere continues to engage in academic and research activities. Her involvement in ongoing research projects reflects her commitment to advancing the field of occupational health. By focusing on industries with high exposure risks, such as ferrosilicon production and oncology nursing, she highlights the often-overlooked dangers in these environments, contributing to the improvement of workplace health standards.

Contributions and Research Focus 🔬

One of Tahere’s notable research contributions includes a study titled “Evaluating oxidative stress biomarkers in oncology nurses exposed to antineoplastic drugs: A cross-sectional study”, which is indexed in Scopus. This research delved into the oxidative stress faced by nurses who are regularly exposed to antineoplastic drugs, which are commonly used in cancer treatments. The study provided valuable data on the biomarkers associated with oxidative stress in these healthcare workers, emphasizing the need for better protective measures and health monitoring in hospitals and oncology departments.

Her current research focuses on the ferrosilicon industry, where she is studying the impact of chemical exposure on workers’ health. The goal of this study is to identify key biomarkers of oxidative stress and other health concerns that can arise from prolonged exposure to industrial chemicals, with a view to proposing solutions that can mitigate these risks. Through these projects, Tahere has made a significant contribution to both the occupational health and healthcare fields by addressing the unseen risks faced by workers.

Accolades and Recognition 🏆

While still early in her career, Tahere Abdollahi has already gained recognition for her research work, particularly her study on oxidative stress in oncology nurses. This research has been published in a Scopus-indexed journal, an achievement that speaks to the quality and relevance of her work. Her contribution to occupational health through her research is commendable, and her work has the potential to influence safety regulations and practices in healthcare settings.

Tahere has also applied for the Best Researcher Award in the international top pharmaceutical awards, which would serve as a well-deserved recognition for her ongoing dedication and impactful work in the field of occupational health.

Impact and Influence 🌍

The research and professional contributions of Tahere Abdollahi extend beyond academia. Her work on evaluating oxidative stress biomarkers among healthcare professionals has highlighted the potential long-term health risks faced by oncology nurses and other healthcare workers. This has led to a broader discussion in medical circles about improving safety protocols and protective measures for workers exposed to hazardous substances in hospitals and medical settings.

Her influence is also being felt in the industrial sector, where her ongoing research on ferrosilicon industries could lead to substantial improvements in workplace safety standards. By focusing on the health risks associated with chemical exposure, she is helping to drive the development of better monitoring systems and protective measures for workers in high-risk industries.

Legacy and Future Contributions 🌟

As an emerging researcher and consultant, Tahere Abdollahi’s future contributions are poised to have a lasting impact on occupational health, particularly in high-risk industries such as healthcare and chemical manufacturing. Her studies on oxidative stress and chemical exposure have the potential to influence policy changes and lead to more stringent safety regulations, benefiting workers across a wide range of sectors.

Her ongoing research promises to add further depth to her already impressive body of work, with a focus on enhancing worker safety and health in environments where exposure to hazardous substances is common. Tahere is likely to continue collaborating with experts across industries, contributing her knowledge and expertise to safeguard the health of countless workers.

In the years to come, her legacy will likely include being a key advocate for worker safety in occupational health. Her work will not only serve as a blueprint for future researchers but will also drive real-world changes in occupational safety standards.

Conclusion ✨

Tahere Abdollahi is a rising star in the field of occupational health engineering. Her academic and professional background, coupled with her impactful research on healthcare workers and industrial safety, positions her as an influential figure in her field. Through her work, she continues to champion the health and safety of workers, and her ongoing contributions are sure to leave a lasting mark on occupational health practices and policies worldwide.

🎓Publication 

Evaluating oxidative stress biomarkers in oncology nurses exposed to antineoplastic drugs: A cross-sectional study

  • Authors   : Abdollahi, T.; Ranjbar, A.; Faradmal, J.; Mohraz, M.H.; Assari, M.J.
  • Journal    :Oncology Nursing
  • Year         :2024